R A Brekken
Affiliation: The Hope Heart Institute
- Vascular endothelial growth factor and vascular targeting of solid tumorsR A Brekken
The Hope Heart Institute, Department of Vascular Biology, Seattle, WA 98104 2046, USA
Anticancer Res 21:4221-9. 2001..We conclude that 2C3 might have dual activity as an anti-angiogenic agent by inhibiting VEGFR2 activity and as a vascular targeting agent for selective drug delivery to tumor vessels...
- VEGF-VEGF receptor complexes as markers of tumor vascular endotheliumR A Brekken
The Hope Heart Institute, Department of Vascular Biology, 1124 Columbia St, Seattle, WA 98104-2046, USA
J Control Release 74:173-81. 2001..2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex...
- Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null miceA D Bradshaw
Department of Vascular Biology, The Hope Heart Institute, University of Washington, Seattle, Washington 98104, USA
Wound Repair Regen 9:522-30. 2001....
- SPARC, a matricellular protein: at the crossroads of cell-matrix communicationR A Brekken
The Department of Vascular Biology, The Hope Heart Institute, 1124 Columbia St, Seattle, WA 98104, USA
Matrix Biol 19:816-27. 2001..SPARC is a prototypical matricellular protein that functions to regulate cell-matrix interactions and thereby influences many important physiological and pathological processes...